<DOC>
	<DOCNO>NCT00822185</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial ass safety tolerability activate recombinant human coagulation factor VII analogue ( NN1731 , vatreptacog alfa ( activate ) ) healthy Japanese male subject . In addition , pharmacokinetics NN1731 examine</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics NN1731 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Japanese male subject , consider generally healthy base assessment medical history , physical examination clinical laboratory data screening , judge Investigator Subinvestigator Body Mass Index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Any clinical laboratory value deviate reference range laboratory ( except case within physiological change ) abnormal electrocardiogram ( ECG ) finding screen , judge Investigator Subinvestigator Presence history cancer clinically significant cardiac , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , dermatological , venereal , haematological , neurological , psychiatric disease disorder Evidence clinically relevant pathology potential thromboembolic risk judge Investigator Subinvestigator Presence history atherosclerosis , arteriosclerosis thromboembolic event Any past history migraine Overt bleeding , include gastrointestinal tract</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>